Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shannon N Westin

Showing results (1-10 of 210) with videos related to

Pageof 21
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 7, 2022
Should secondary cytoreduction be used in recurrent ovarian cancer?Shannon N Westin
Gynecologic Oncology|January 26, 2016
The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topicsShannon N Westin, Leslie Randall
Gynecologic Oncology|March 27, 2016
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowJoyce Liu, Shannon N Westin
Gynecologic Oncology|November 10, 2021
Next generation sequencing for gynecologic malignancy: Promise and potential pitfallsEmily M Hinchcliff, Shannon N Westin
Cancer Biology & Therapy|December 27, 2011
Personalized therapy in endometrial cancer: challenges and opportunitiesShannon N Westin, Russell R Broaddus
Gynecologic Oncology|January 17, 2017
Individualized Medicine in Ovarian Cancer: Are We There Yet?Shannon N Westin, Robert L Coleman
Drugs|August 28, 2020
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian CancerMichaela Onstad, Robert L Coleman, Shannon N Westin
Gynecologic Oncology|May 19, 2022
State of the science: Contemporary front-line treatment of advanced ovarian cancerEmily Hinchcliff, Shannon N Westin, Thomas J Herzog
BMC Cancer|October 18, 2015
Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case reportLaura L Holman, Yulan Ren, Shannon N Westin
Current Opinion in Obstetrics & Gynecology|December 14, 2020
Current and future landscape of poly (ADP-ribose) polymerase inhibition resistanceEmily Hinchcliff, Anca Chelariu-Raicu, Shannon N Westin
Pageof 21

Showing results (1-10 of 210) with videos related to

Sort By:
Pageof 21
Clinical Advances in Hematology & Oncology : H&O|April 7, 2022
Should secondary cytoreduction be used in recurrent ovarian cancer?Shannon N Westin
Gynecologic Oncology|January 26, 2016
The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topicsShannon N Westin, Leslie Randall
Gynecologic Oncology|March 27, 2016
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowJoyce Liu, Shannon N Westin
Gynecologic Oncology|November 10, 2021
Next generation sequencing for gynecologic malignancy: Promise and potential pitfallsEmily M Hinchcliff, Shannon N Westin
Cancer Biology & Therapy|December 27, 2011
Personalized therapy in endometrial cancer: challenges and opportunitiesShannon N Westin, Russell R Broaddus
Gynecologic Oncology|January 17, 2017
Individualized Medicine in Ovarian Cancer: Are We There Yet?Shannon N Westin, Robert L Coleman
Drugs|August 28, 2020
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian CancerMichaela Onstad, Robert L Coleman, Shannon N Westin
Gynecologic Oncology|May 19, 2022
State of the science: Contemporary front-line treatment of advanced ovarian cancerEmily Hinchcliff, Shannon N Westin, Thomas J Herzog
BMC Cancer|October 18, 2015
Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case reportLaura L Holman, Yulan Ren, Shannon N Westin
Current Opinion in Obstetrics & Gynecology|December 14, 2020
Current and future landscape of poly (ADP-ribose) polymerase inhibition resistanceEmily Hinchcliff, Anca Chelariu-Raicu, Shannon N Westin
Pageof 21